Section Arrow
VYNE.NASDAQ
- VYNE Therapeutics
Quotes are at least 15-min delayed:2025/06/02 15:20 EDT
Last
 0.9289
-0.0211 (-2.22%)
Day High 
0.979 
Prev. Close
0.95 
1-M High
1.44 
Volume 
227.11K 
Bid
0.9251
Ask
0.929
Day Low
0.92 
Open
0.965 
1-M Low
0.95 
Market Cap 
15.83M 
Currency USD 
P/E 0.67 
%Yield -- 
10-SMA 1.05 
20-SMA 1.19 
50-SMA 1.46 
52-W High 4.3 
52-W Low 0.95 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.98/-0.59
Enterprise Value
15.83M
Balance Sheet
Book Value Per Share
2.65
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
501.00K
Operating Revenue Per Share
0.02
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OGENOragenics0.1718+0.0518+43.17%-- 
PSTVPlus Therapeutics0.3949+0.108+37.64%-- 
PCSAProcessa Pharmaceuticals0.2979+0.0054+1.85%-- 
BPMCBlueprint Medicines Corp127.58+26.23+25.88%-- 
NCNANuCana plc0.0374+0.0021+5.95%-- 
Quotes are at least 15-min delayed:2025/06/02 15:20 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.